Rivaroxaban 20 MG Oral Tablet
Sponsors
The Affiliated Hospital of Qingdao University, University of Karachi, Addpharma Inc., University of Sao Paulo General Hospital, Peshawar Institute of Cardiology
Conditions
Atrial Fibrillation New OnsetBioequivalenceBreast Milk CollectionBreastfeedingCerebral Venous Sinus ThrombosisCerebral Venous ThrombosisCoagulation DisorderEmbolism and Thrombosis
Phase 1
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
CompletedNCT04424381
Start: 2019-06-04End: 2019-09-20Updated: 2020-06-11
Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions
CompletedNCT04689919
Start: 2022-02-19End: 2022-04-05Updated: 2022-09-07
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
CompletedNCT05128591
Start: 2021-11-09End: 2021-12-31Updated: 2022-03-08
Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
Active, not recruitingNCT06372483
Start: 2024-02-21End: 2026-08-31Updated: 2024-11-18
Excretion of Rivaroxaban in Human Breast Milk
RecruitingNCT06831474
Start: 2025-07-31End: 2026-07-31Target: 10Updated: 2025-07-17
Phase 3
Phase 4
Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery
NCT05300555
Start: 2021-01-05End: 2022-11-01Target: 50Updated: 2022-03-29
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
NCT05973188
Start: 2023-05-01End: 2024-06-30Target: 141Updated: 2023-08-02